

Terry L Ng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/539970/publications.pdf>

Version: 2024-02-01

39
papers

716
citations

858243

12
h-index

620720

26
g-index

39
all docs

39
docs citations

39
times ranked

1196
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. <i>Science Advances</i> , 2019, 5, eaav2437.	4.7	92
2	Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review. <i>Oncologist</i> , 2015, 20, 210-223.	1.9	91
3	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-L1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 1038-1049.	2.0	66
4	Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?. <i>Oncologist</i> , 2015, 20, 576-583.	1.9	62
5	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. <i>Journal of Thoracic Oncology</i> , 2019, 14, 596-605.	0.5	56
6	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9010-9010.	0.8	40
7	Defining optimal control of chemotherapy-induced nausea and vomiting based on patients' experience. <i>Supportive Care in Cancer</i> , 2015, 23, 3341-3359.	1.0	37
8	Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 1-8.	1.1	33
9	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. <i>Lung Cancer</i> , 2018, 125, 115-120.	0.9	29
10	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Supportive Care in Cancer</i> , 2021, 29, 925-943.	1.0	28
11	Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1190-1199.	0.5	23
12	Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 337-344.	1.1	15
13	Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. <i>Lung Cancer</i> , 2018, 126, 112-118.	0.9	14
14	Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer – An inspection of the evidence base informing clinical decision-making. <i>Cancer Treatment Reviews</i> , 2015, 41, 951-959.	3.4	12
15	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. <i>Bladder Cancer</i> , 2019, 5, 131-145.	0.2	11
16	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. <i>Clinical Lung Cancer</i> , 2019, 20, e39-e51.	1.1	11
17	The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103540.	2.0	11
18	Long-term benefits versus side-effects from bone-targeted therapies for cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 420-428.	0.5	10

#	ARTICLE	IF	CITATIONS
19	Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. <i>Journal of Bone Oncology</i> , 2021, 26, 100339.	1.0	10
20	Aprepitant Versus Dexamethasone to Prevent Delayed Emesis After Chemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 2184-2185.	0.8	7
21	Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion. <i>Translational Lung Cancer Research</i> , 2020, 9, 1452-1463.	1.3	7
22	Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. <i>Journal of Bone Oncology</i> , 2021, 26, 100343.	1.0	6
23	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 5787-5795.	1.0	6
24	Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. <i>Supportive Care in Cancer</i> , 2021, 29, 6903-6912.	1.0	6
25	Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey. <i>Current Oncology</i> , 2021, 28, 5215-5226.	0.9	6
26	Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. <i>Supportive Care in Cancer</i> , 2022, 30, 3977-3984.	1.0	5
27	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. <i>Current Oncology</i> , 2021, 28, 5073-5083.	0.9	5
28	Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. <i>Journal of Bone Oncology</i> , 2021, 27, 100351.	1.0	4
29	A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. <i>Breast</i> , 2021, 58, 42-49.	0.9	4
30	Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 1847-1856.	0.9	3
31	Association of anticoagulant use with clinical outcomes from crizotinib in ALK rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001. <i>Cancer Medicine</i> , 2022, , .	1.3	2
32	Skeletal-related events (SRE) and bone-targeted agents for metastatic prostate cancer: Are we changing outcomes?. <i>Journal of Clinical Oncology</i> , 2013, 31, e16074-e16074.	0.8	1
33	Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24083-e24083.	0.8	1
34	Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2022, 30, 5627-5644.	1.0	1
35	Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial). <i>Cancer Research</i> , 2022, 82, OT1-01-01-OT1-01-01.	0.4	1
36	Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation. <i>Journal of Thoracic Oncology</i> , 2021, 16, 486-491.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Is there a role for oral or intravenous ascorbate (vitamin C) treatment for patients with cancer? A systematic review.. Journal of Clinical Oncology, 2014, 32, e20598-e20598.	0.8	0
38	Antiemetic recommendations for breast cancer patients receiving highly emetogenic chemotherapy: A systematic review incorporating network meta-analyses.. Journal of Clinical Oncology, 2014, 32, e17608-e17608.	0.8	0
39	Early pulmonary function changes associated with brigatinib initiation.. Journal of Clinical Oncology, 2020, 38, 9538-9538.	0.8	0